Skip to main content

Evanko Brian C's Form 4 filing

Cigna GroupCI · filed Jun 26, 2024

Accession no.
0001225208-24-007005
Filed
Jun 26, 2024
Trade date
Jun 24-25, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.65M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Evanko Brian CCIK 0001722909Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 24, 2024Common Stock, $.01 Par ValueMOption exerciseAcquired+4,795$120.90+$579,715.544,718Direct
Jun 24, 2024Common Stock, $.01 Par ValueSSaleDisposed−4,795$345.01F2−$1,654,322.9539,923Direct
Jun 25, 2024Common Stock, $.01 Par ValueMOption exerciseAcquired+1,011$120.90+$122,229.940,934Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 24, 2024Common Stock, $.01 Par ValueMOption exerciseDisposed−4,795$0.00$01,011Direct
Jun 25, 2024Common Stock, $.01 Par ValueMOption exerciseDisposed−1,011$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average price of the shares sold. The prices actually received ranged from $345.00 to $345.07 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Remarks

EVP, Chief Financial Officer and President & CEO, Cigna Healthcare

Read the full filing on SEC EDGAR (opens in a new tab)